Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Early Feasibility Study of the Cardiovalve System for Tricuspid Regurgitation

NCT: NCT04100720 · WITHDRAWN

NCT IDNCT04100720
StatusWITHDRAWN
Start Date2024-02
Completion2030-12

Brief Summary

This study is to evaluate the safety and technical performance of the Cardiovalve Transfemoral System for tricuspid valve replacement. Data collected in the clinical study will include 30-day safety and performance of the device and delivery system, and long-term clinical outcomes over a follow-up of 5 years.

Frequently Asked Questions

What is Early Feasibility Study of the Cardiovalve System for Tricuspid Regurgitation?

Early Feasibility Study of the Cardiovalve System for Tricuspid Regurgitation is a clinical trial registered under NCT04100720. Current status: WITHDRAWN.

What is the status of NCT04100720?

The current status of NCT04100720 (Early Feasibility Study of the Cardiovalve System for Tricuspid Regurgitation) is: WITHDRAWN.

When did Early Feasibility Study of the Cardiovalve System for Tricuspid Regurgitation start?

Early Feasibility Study of the Cardiovalve System for Tricuspid Regurgitation started on 2024-02.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑